Abstract 6P
Background
PD-1-based immunotherapy is used for first- or second-line therapeutic regimens against NSCLC. Anti-PD-1 immunotherapy resistance occurs in diabetic patients with NSCLC. However, the characteristics of immune cell infiltration in such patients remain unexplored. Thus, we investigated the possible link between diabetes and immune cell infiltration in NSCLC.
Methods
We included patients (n = 437) with NSCLC treated with anti-PD-1 immunotherapy from the Zhejiang University School of Medicine. We analyzed the objective response rate, progression-free survival (PFS), overall survival (OS), T-cell infiltration, and peripheral blood immunological characteristics in diabetic and nondiabetic NSCLC patients. Differences in tumor microenvironment profiles were measured using CyTOF to elucidate the reasons for poor PFS and OS in diabetic NSCLC patients.
Results
Nondiabetic NSCLC patients had longer PFS than diabetic NSCLC patients (11.0 vs 7.0 months). The OS was 24.0 and 17.0 months in nondiabetic and diabetic NSCLC patients, respectively (P = 0.0065). Diabetic NSCLC patients had significantly lower CD8+T cell infiltration than nondiabetic NSCLC patients (P = 0.0227). Similarly, the anti-tumor effect of PD-1 blockade was decreased in diabetic mice with lung cancer. Additionally, compared with nondiabetic NSCLC patients before anti-PD1 treatment, CyTOF analysis showed that diabetic NSCLC patients had significantly more CD161+CD127+CD8+ T cells (P = 0.0071), and this trend continued after anti-PD1 treatment (P = 0.0393). Flow cytometry showed that diabetic NSCLC patients had a significantly higher CD161+CD127+CD8+T/CD8+ T cells ratio than nondiabetic NSCLC patients. Kaplan–Meier survival analysis showed that high levels of CD161+CD127+CD8+ T cells were positively related to the PFS in diabetic NSCLC patients.
Conclusions
We confirmed that diabetes is a risk factor for patients with NSCLC who undergo anti-PD-1 immunotherapy. CD161+CD127+CD8+ T cells in diabetic NSCLC patients serve as a key indicator of poor prognosis. Our findings provide a reference for understanding the characteristics of the tumor microenvironment in diabetic NSCLC patients.
Editorial acknowledgement
Prof. Nong Yang from the Lung Cancer and Gastroenterology Department, Hunan Cancer Hospital, and the Affiliated Tumor Hospital of Xiangya Medical School of Central South University for their technical support. Editage for English language editing.
Legal entity responsible for the study
Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.
Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81802278), Natural Science Foundation of Zhejiang Province (No.LY23H160020), Medicine Health Technology Plan of Zhejiang Province, China (No. 2022KY150), and General Project of Education Department of Zhejiang Province (Y202043420).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1P - Integrated Data Analysis within IMMUcan Identifies Prognostic Features of Early NSCLC
Presenter: Daniel Schulz
Session: Poster Display
3P - Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study
Presenter: Luis Paz-Ares
Session: Poster Display
4P - Immune exoproteome, soluble proteome and immune-related gene expression profiles of anti-PD-1 therapy in stage IIIB/IV Non-Small Cell Lung Cancer: relevance of immunosuppressive factors
Presenter: Paulo Santos
Session: Poster Display
5P - Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC
Presenter: Giulia Mazzaschi
Session: Poster Display
7P - A T-cell-derived circulating DNA as a biomarker for response to anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer
Presenter: Nuthchaya Mejun
Session: Poster Display
9P - Primary NSCLC patient-derived microtumors (PMTs) for clinical-relvant prediction of immunotherapy efficacy
Presenter: Fabienne Nocera
Session: Poster Display
11P - Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
Presenter: Liang Zheng
Session: Poster Display
12P - Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Melina Peressini Álvarez
Session: Poster Display
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display